[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis
In simplest terms, obesity first means we treat obesity as a priority when confronting these obesity-associated disorders
In tests on animal models, wounds showed faster contraction, better epithelialisation, more granulation tissue, and higher antioxidant enzyme activity [5,6]
Medications originally developed to manage type 2 diabetes and obesity are now the subject of rigorous clinical trials investigating their potential to treat addiction and the early results are generating serious optimism among researchers and clinicians alike
Oral Supplements While daily vitamins have their place, IV therapy offers distinct advantages